Literature DB >> 8183246

Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program.

I Posner1, M Engel, A Gazit, A Levitzki.   

Abstract

The kinetics of inhibition of the epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase (TK) activity by erbstatin, tyrphostins, and lavendustin derivatives were studied in a system that employs poly(Glu6Ala3Tyr) (GAT) and ATP as substrates, after preactivation with EGF. All data were analyzed for computer best-fit curves by a program that was written for this purpose and is available upon request to those interested. The inhibition kinetics followed a sequential, Bi-Bi, rapid equilibrium, random mechanism, the mechanism of the EGFR-TK. Erbstatin and a few tyrphostins that contain a 3,4-dihydroxy-(cis)-cinnamonitrile [1-(3',4'-dihydroxyphenyl)-2-nitriloethene] group were found to be pure competitive inhibitors with respect to both substrates of the kinase reaction, i.e., GAT and ATP. Two tyrphostins, each containing an additional dihydroxyphenyl group in the alpha-position, were found to be pure competitive inhibitors with respect to GAT and noncompetitive (or mixed-competitive) inhibitors with respect to ATP. A lavendustin derivative with a 2,5-dihydroxyphenyl ring and a lavendustin derivative with a 3,4-dihydroyphenyl ring were also found to be competitive inhibitors with respect to both ATP and GAT. Various possible modes of binding at the EGFR-TK active center for the tyrphostins studied are proposed and the significance of the present findings, as well as the interpretations of computer analyses of kinetic data, is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8183246

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Inhibition of fast sodium current in rabbit ventricular myocytes by protein tyrosine kinase inhibitors.

Authors:  Yanggan Wang; Mary B Wagner; Rajiv Kumar; Jun Cheng; Ronald W Joyner
Journal:  Pflugers Arch       Date:  2003-04-26       Impact factor: 3.657

2.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

3.  Therapeutic destruction of insulin receptor substrates for cancer treatment.

Authors:  Hadas Reuveni; Efrat Flashner-Abramson; Lilach Steiner; Kirill Makedonski; Renduo Song; Alexei Shir; Meenhard Herlyn; Menashe Bar-Eli; Alexander Levitzki
Journal:  Cancer Res       Date:  2013-05-07       Impact factor: 12.701

4.  Conformational changes accompany phosphorylation of the epidermal growth factor receptor C-terminal domain.

Authors:  Nam Y Lee; John G Koland
Journal:  Protein Sci       Date:  2005-09-30       Impact factor: 6.725

Review 5.  Signal transduction pathways and their relevance in human astrocytomas.

Authors:  M M Feldkamp; N Lau; A Guha
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

Review 6.  Targeting HER (ERBB) signaling in head and neck cancer: An essential update.

Authors:  Jun Zhang; Nabil F Saba; Georgia Zhuo Chen; Dong M Shin
Journal:  Mol Aspects Med       Date:  2015-07-07

7.  Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV+ and HPV- Squamous Cell Carcinoma.

Authors:  Benjamin Kansy; Christoph Aderhold; Lena Huber; Sonja Ludwig; Richard Birk; Anne Lammert; Stephan Lang; Nicole Rotter; Benedikt Kramer
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

Review 8.  The epidermal growth factor receptor pathway in chronic kidney diseases.

Authors:  Laura R Harskamp; Ron T Gansevoort; Harry van Goor; Esther Meijer
Journal:  Nat Rev Nephrol       Date:  2016-07-04       Impact factor: 28.314

Review 9.  Platelet-derived growth factors and their receptors: structural and functional perspectives.

Authors:  Po-Han Chen; Xiaoyan Chen; Xiaolin He
Journal:  Biochim Biophys Acta       Date:  2012-11-05

10.  Suppression of insulin signalling by a synthetic peptide KIFMK suggests the cytoplasmic linker between DIII-S6 and DIV-S1 as a local anaesthetic binding site on the sodium channel.

Authors:  Munetaka Hirose; Yoshihiro Kuroda; Shinichi Sawa; Terumichi Nakagawa; Masashi Hirata; Masahiro Sakaguchi; Yoshifumi Tanaka
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.